-
PDF
- Split View
-
Views
-
Cite
Cite
Erratum, JNCI: Journal of the National Cancer Institute, Volume 101, Issue 18, 16 September 2009, Page 1291, https://doi.org/10.1093/jnci/djp204
Close - Share Icon Share
Erratum: “Alterations in the TOP2A and HER2 Genes: Association with Adjuvant Anthracycline Sensitivity in Human Breast Cancers” by Slamon and Press [ J Natl Cancer Inst 2009; 101(9): 615–618 ]. The spacing in columns 2, 4, 5, and 7 of Table 1 was altered during typesetting such that the data were incorrectly displayed in each row. The correct version of Table 1 appears below. The Journal and the authors regret the error.
Table 1
Prevalence of TOP2A alterations (amplification and deletion) by HER2 status in published studies *
| HER2-positive (%) | HER2-negative (%) | ||||||
| Number in Study | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | First author, year (reference) |
| 354 | 73/354 (21%) | 281/354 (89%) | Di Leo, 2002 (27) | ||||
| 23/61 (38%) | 30/61 (49%) | 8/61 (13%) | ND | ND | ND | ||
| 120 | 30/120 (25%) | 90/120 (75%) † | Olsen, 2004 (28) | ||||
| 10/30 (33%) | 14/30 (47%) | 6/30 (20%) | 1/90 (1.1%) | 86/90 (95.5%) | 3/90 (3.3%) | ||
| 805 | 263/805 (32.6%) † | 542/805 (67.3%) † | Knoop, 2005 (29) | ||||
| 79/263 (30%) | 106/263 (40.3%) | 60/263 (22.8%) | 14/542 (2.6%) | 502/542 (92.7%) | 26/542 (4.7%) | ||
| 391 | 128/391 (32.7%) ‡ | 263/391 (67.3) ‡ | Tanner, 2006 (30) | ||||
| 48/128 (37.5%) | 80/128 (62.5%) | ND | ND | ND | ND | ||
| 284 | 74/284 (26%) | 210/284 (74%) | Park, 2006 (31) | ||||
| 18/74 (24.3%) | 50/74 (67.5%) | 6/74 (8.1%) | 2/210 (1%) | 208/210 (99%) | 0/210 (0%) | ||
| 351 | 94/351 (26.8%) | 257/351 (73.2%) | Konecny, 2006 (32) | ||||
| 40/94 (42.6%) | 37/94 (39.4%) | 17/94 (18%) | 0/257 (0%) | 257/257 (100%) | 0/257 (0%) | ||
| 245 | 37/233 (15.9%) ‡ | 196/233 (84.1%) ‡ | Arriola, 2007 (33) | ||||
| 20/37 (54%) | 17/37 (46%) | ND | 0/196 (0%) | 196/196 (100%) | ND | ||
| 303 | 63/303 (20.8%) | 240/303 (79.2%) | Bartlett, 2008 (34) | ||||
| 17/63 (27%) | 24/63 (38%) | 22/63 (35%) | 9/240 (3.8%) | 203/240 (84.6%) | 28/240 (11.7%) | ||
| 2,853 | 762/2841 (26.8%) | 2079/2841 (73.2%) | Totals | ||||
| 255/750 (34%) | 358/750 (47.7%) | 119/585 (20.3%) | 26/1535 (1.6%) | 1452/1535 (94.6%) | 57/1339 (4.2%) | ||
| 438 | 116/438 (26.5%) | 314/438 (71.7%) | O'Malley, 2009 (1) | ||||
| 33/116 (28.4%) | 66/116 (56.9%) | 17/116 (14.7%) | 20/314 (6.4%) | 285/314 (90.8%) | 9/314 (2.9%) | ||
| HER2-positive (%) | HER2-negative (%) | ||||||
| Number in Study | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | First author, year (reference) |
| 354 | 73/354 (21%) | 281/354 (89%) | Di Leo, 2002 (27) | ||||
| 23/61 (38%) | 30/61 (49%) | 8/61 (13%) | ND | ND | ND | ||
| 120 | 30/120 (25%) | 90/120 (75%) † | Olsen, 2004 (28) | ||||
| 10/30 (33%) | 14/30 (47%) | 6/30 (20%) | 1/90 (1.1%) | 86/90 (95.5%) | 3/90 (3.3%) | ||
| 805 | 263/805 (32.6%) † | 542/805 (67.3%) † | Knoop, 2005 (29) | ||||
| 79/263 (30%) | 106/263 (40.3%) | 60/263 (22.8%) | 14/542 (2.6%) | 502/542 (92.7%) | 26/542 (4.7%) | ||
| 391 | 128/391 (32.7%) ‡ | 263/391 (67.3) ‡ | Tanner, 2006 (30) | ||||
| 48/128 (37.5%) | 80/128 (62.5%) | ND | ND | ND | ND | ||
| 284 | 74/284 (26%) | 210/284 (74%) | Park, 2006 (31) | ||||
| 18/74 (24.3%) | 50/74 (67.5%) | 6/74 (8.1%) | 2/210 (1%) | 208/210 (99%) | 0/210 (0%) | ||
| 351 | 94/351 (26.8%) | 257/351 (73.2%) | Konecny, 2006 (32) | ||||
| 40/94 (42.6%) | 37/94 (39.4%) | 17/94 (18%) | 0/257 (0%) | 257/257 (100%) | 0/257 (0%) | ||
| 245 | 37/233 (15.9%) ‡ | 196/233 (84.1%) ‡ | Arriola, 2007 (33) | ||||
| 20/37 (54%) | 17/37 (46%) | ND | 0/196 (0%) | 196/196 (100%) | ND | ||
| 303 | 63/303 (20.8%) | 240/303 (79.2%) | Bartlett, 2008 (34) | ||||
| 17/63 (27%) | 24/63 (38%) | 22/63 (35%) | 9/240 (3.8%) | 203/240 (84.6%) | 28/240 (11.7%) | ||
| 2,853 | 762/2841 (26.8%) | 2079/2841 (73.2%) | Totals | ||||
| 255/750 (34%) | 358/750 (47.7%) | 119/585 (20.3%) | 26/1535 (1.6%) | 1452/1535 (94.6%) | 57/1339 (4.2%) | ||
| 438 | 116/438 (26.5%) | 314/438 (71.7%) | O'Malley, 2009 (1) | ||||
| 33/116 (28.4%) | 66/116 (56.9%) | 17/116 (14.7%) | 20/314 (6.4%) | 285/314 (90.8%) | 9/314 (2.9%) | ||
*
Study populations of 100 or more women. TOP2A = topoisomerase II alpha; HER2 = human epidermal growth factor receptor type 2; ND = not determined.
†
HER2 status determined by immunohistochemistry.
‡
HER2 status determined by chromogenic in situ hybridization.
Table 1
Prevalence of TOP2A alterations (amplification and deletion) by HER2 status in published studies *
| HER2-positive (%) | HER2-negative (%) | ||||||
| Number in Study | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | First author, year (reference) |
| 354 | 73/354 (21%) | 281/354 (89%) | Di Leo, 2002 (27) | ||||
| 23/61 (38%) | 30/61 (49%) | 8/61 (13%) | ND | ND | ND | ||
| 120 | 30/120 (25%) | 90/120 (75%) † | Olsen, 2004 (28) | ||||
| 10/30 (33%) | 14/30 (47%) | 6/30 (20%) | 1/90 (1.1%) | 86/90 (95.5%) | 3/90 (3.3%) | ||
| 805 | 263/805 (32.6%) † | 542/805 (67.3%) † | Knoop, 2005 (29) | ||||
| 79/263 (30%) | 106/263 (40.3%) | 60/263 (22.8%) | 14/542 (2.6%) | 502/542 (92.7%) | 26/542 (4.7%) | ||
| 391 | 128/391 (32.7%) ‡ | 263/391 (67.3) ‡ | Tanner, 2006 (30) | ||||
| 48/128 (37.5%) | 80/128 (62.5%) | ND | ND | ND | ND | ||
| 284 | 74/284 (26%) | 210/284 (74%) | Park, 2006 (31) | ||||
| 18/74 (24.3%) | 50/74 (67.5%) | 6/74 (8.1%) | 2/210 (1%) | 208/210 (99%) | 0/210 (0%) | ||
| 351 | 94/351 (26.8%) | 257/351 (73.2%) | Konecny, 2006 (32) | ||||
| 40/94 (42.6%) | 37/94 (39.4%) | 17/94 (18%) | 0/257 (0%) | 257/257 (100%) | 0/257 (0%) | ||
| 245 | 37/233 (15.9%) ‡ | 196/233 (84.1%) ‡ | Arriola, 2007 (33) | ||||
| 20/37 (54%) | 17/37 (46%) | ND | 0/196 (0%) | 196/196 (100%) | ND | ||
| 303 | 63/303 (20.8%) | 240/303 (79.2%) | Bartlett, 2008 (34) | ||||
| 17/63 (27%) | 24/63 (38%) | 22/63 (35%) | 9/240 (3.8%) | 203/240 (84.6%) | 28/240 (11.7%) | ||
| 2,853 | 762/2841 (26.8%) | 2079/2841 (73.2%) | Totals | ||||
| 255/750 (34%) | 358/750 (47.7%) | 119/585 (20.3%) | 26/1535 (1.6%) | 1452/1535 (94.6%) | 57/1339 (4.2%) | ||
| 438 | 116/438 (26.5%) | 314/438 (71.7%) | O'Malley, 2009 (1) | ||||
| 33/116 (28.4%) | 66/116 (56.9%) | 17/116 (14.7%) | 20/314 (6.4%) | 285/314 (90.8%) | 9/314 (2.9%) | ||
| HER2-positive (%) | HER2-negative (%) | ||||||
| Number in Study | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | TOP2A -Ampl No. (%) | TOP2A -Normal No. (%) | TOP2A -Deleted No. (%) | First author, year (reference) |
| 354 | 73/354 (21%) | 281/354 (89%) | Di Leo, 2002 (27) | ||||
| 23/61 (38%) | 30/61 (49%) | 8/61 (13%) | ND | ND | ND | ||
| 120 | 30/120 (25%) | 90/120 (75%) † | Olsen, 2004 (28) | ||||
| 10/30 (33%) | 14/30 (47%) | 6/30 (20%) | 1/90 (1.1%) | 86/90 (95.5%) | 3/90 (3.3%) | ||
| 805 | 263/805 (32.6%) † | 542/805 (67.3%) † | Knoop, 2005 (29) | ||||
| 79/263 (30%) | 106/263 (40.3%) | 60/263 (22.8%) | 14/542 (2.6%) | 502/542 (92.7%) | 26/542 (4.7%) | ||
| 391 | 128/391 (32.7%) ‡ | 263/391 (67.3) ‡ | Tanner, 2006 (30) | ||||
| 48/128 (37.5%) | 80/128 (62.5%) | ND | ND | ND | ND | ||
| 284 | 74/284 (26%) | 210/284 (74%) | Park, 2006 (31) | ||||
| 18/74 (24.3%) | 50/74 (67.5%) | 6/74 (8.1%) | 2/210 (1%) | 208/210 (99%) | 0/210 (0%) | ||
| 351 | 94/351 (26.8%) | 257/351 (73.2%) | Konecny, 2006 (32) | ||||
| 40/94 (42.6%) | 37/94 (39.4%) | 17/94 (18%) | 0/257 (0%) | 257/257 (100%) | 0/257 (0%) | ||
| 245 | 37/233 (15.9%) ‡ | 196/233 (84.1%) ‡ | Arriola, 2007 (33) | ||||
| 20/37 (54%) | 17/37 (46%) | ND | 0/196 (0%) | 196/196 (100%) | ND | ||
| 303 | 63/303 (20.8%) | 240/303 (79.2%) | Bartlett, 2008 (34) | ||||
| 17/63 (27%) | 24/63 (38%) | 22/63 (35%) | 9/240 (3.8%) | 203/240 (84.6%) | 28/240 (11.7%) | ||
| 2,853 | 762/2841 (26.8%) | 2079/2841 (73.2%) | Totals | ||||
| 255/750 (34%) | 358/750 (47.7%) | 119/585 (20.3%) | 26/1535 (1.6%) | 1452/1535 (94.6%) | 57/1339 (4.2%) | ||
| 438 | 116/438 (26.5%) | 314/438 (71.7%) | O'Malley, 2009 (1) | ||||
| 33/116 (28.4%) | 66/116 (56.9%) | 17/116 (14.7%) | 20/314 (6.4%) | 285/314 (90.8%) | 9/314 (2.9%) | ||
*
Study populations of 100 or more women. TOP2A = topoisomerase II alpha; HER2 = human epidermal growth factor receptor type 2; ND = not determined.
†
HER2 status determined by immunohistochemistry.
‡
HER2 status determined by chromogenic in situ hybridization.
Published by Oxford University Press 2009.
